In a wide-ranging interview, AbbVie’s Linn Mandahl discusses how the reorganisation of Scandinavian operations back in 2018 has put the company back on a growth trajectory in the region. Mandahl also touches on the challenges and opportunities in terms of portfolio and culture that the Allergan acquisition has brought about; the market access scenario in Denmark and Sweden; and the potential for greater clinical trial collaboration between the two Nordic nations.
There are a lot of synergies to be leveraged between Allergan and AbbVie, all of which will help create a stronger overall organisation that can provide more to patients beyond simply supplying medication
